AssetMark Inc’s Apellis Pharmaceuticals APLS Stock Holding History

AssetMark Inc’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10	Closed	-$251	–	3446
2025 Q4	$251	Buy	+10	New	+$235	﹤0.01%	3226
2025 Q3	–	Sell	-11	Closed	-$190	–	3189
2025 Q2	$190	Sell	11 -1,241	-99%	-$23K	﹤0.01%	2886
2025 Q1	$27.4K	Buy	1,252 +1,221	+3,939%	+$33.7K	﹤0.01%	1619
2024 Q4	$989	Sell	31 -46,034	-100%	-$1.38M	﹤0.01%	2247
2024 Q3	$1.33M	Buy	46,065 +2,852	+7%	+$106K	﹤0.01%	736
2024 Q2	$1.66M	Buy	43,213 +21,466	+99%	+$972K	0.01%	657
2024 Q1	$1.28M	Buy	21,747 +4,403	+25%	+$281K	﹤0.01%	677
2023 Q4	$1.04M	Buy	17,344 +5,975	+53%	+$303K	﹤0.01%	667
2023 Q3	$432K	Buy	11,369 +5,339	+89%	+$235K	﹤0.01%	783
2023 Q2	$549K	Buy	6,030 +1,220	+25%	+$105K	﹤0.01%	713
2023 Q1	$317K	Buy	+4,810	New	+$278K	﹤0.01%	771

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AssetMark Inc's APLS Position: Q1 2026 in Review

AssetMark Inc sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 10 shares — an estimated $251 sold.

AssetMark Inc first reported a position in APLS in Q1 2023 and held it in 11 quarters. The position peaked at $1.66M in Q2 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

AssetMark Inc reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AssetMark Inc sold 10 Apellis Pharmaceuticals shares in Q1 2026, an estimated $251.
AssetMark Inc first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 11 quarters.
AssetMark Inc's Apellis Pharmaceuticals position peaked at $1.66M in Q2 2024.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.